Long-term study of Zolgensma for spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This study is for people who have already received Zolgensma, a gene therapy for spinal muscular atrophy (SMA). It helps us learn more about how safe and effective the treatment is for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already received the gene therapy Zolgensma.
- You have spinal muscular atrophy (SMA) or a similar condition that was treated with Zolgensma.
- Your treatment must have been approved for your condition (not experimental or under a special research study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study reviews medical records of people with spinal muscular atrophy type 1 who received the gene therapy Zolgensma (onasemnogene abeparvovec) to understand their treatment journey and outcomes. It may help doctors improve care for future patients.
This study tracks how well the gene therapy ITVISMA works in everyday medical practice for people with spinal muscular atrophy (SMA). It aims to see if the treatment is safe and effective in a real-world setting.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.